

HOUSE BILL 826

J1

3lr0816

By: **Delegates Hixson, Boteler, Cardin, Cullison, Frick, Howard, Ivey,
A. Miller, Reznik, Stukes, and F. Turner**

Introduced and read first time: February 6, 2013

Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2 **Maryland Health Care Commission – Personalized Medicine – Study**

3 FOR the purpose of requiring the Maryland Health Care Commission to create a
4 certain stakeholder workgroup to study issues related to the implementation of
5 personalized medicine in the State; requiring the stakeholder workgroup to
6 review certain federal reports and recommendations, conduct a certain analysis,
7 identify certain obstacles to the implementation of personalized medicine, and
8 make certain recommendations; requiring the Commission to make a certain
9 report to certain committees of the General Assembly on or before a certain
10 date; and generally relating to the Maryland Health Care Commission and
11 personalized medicine.

12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
13 MARYLAND, That:

14 (a) The Maryland Health Care Commission shall create a stakeholder
15 workgroup to study issues related to the implementation of personalized medicine in
16 the State.

17 (b) The stakeholder workgroup shall include:

18 (1) representatives from the schools of medicine in the State;

19 (2) representatives from the health insurance industry;

20 (3) representatives from the pharmaceutical industry; and

21 (4) any other interested stakeholder.

22 (c) In conducting the study, the stakeholder workgroup shall:

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 (1) review federal reports and recommendations related to
2 personalized medicine including the President's Council of Advisors on Science and
3 Technology report on Priorities for Personalized Medicine;

4 (2) analyze the impact of the federal Genetic Information
5 Nondiscrimination Act on the State's regulation of personalized medicine;

6 (3) identify obstacles to the implementation of personalized medicine,
7 including:

8 (i) laws and regulations regarding the protection of genetic
9 information;

10 (ii) healthcare worker attitudes, awareness, and education
11 related to personalized medicine;

12 (iii) the use of health information technology;

13 (iv) regulations on the pharmaceutical industry and on
14 laboratories; and

15 (v) reimbursement policies that may reduce access to
16 personalized medicine; and

17 (4) make recommendations, including legislative recommendations, to
18 reduce the obstacles to the implementation of personalized medicine in the State and
19 to otherwise advance the implementation of personalized medicine in the State.

20 (d) On or before December 30, 2013, the Commission shall report the
21 findings and recommendations of the stakeholder workgroup, in accordance with §
22 2-1246 of the State Government Article, to the Senate Finance Committee and the
23 House Health and Government Operations Committee.

24 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
25 June 1, 2013.